Giampaolo Bianchini

Giampaolo Bianchini
专科:
肿瘤科
职业:
肿瘤科医生
医疗机构:
临床肿瘤科 @ 圣拉斐尔科学研究医院
语言:
EN
IT

您需要预约吗？

联系我们，我们将为您妥善安排。
Secure your spot with the doctor
View doctor availability
Send request

个人简介

詹保罗·比安基尼教授（Prof. Giampaolo Bianchini）是米兰圣拉斐尔医院（IRCCS Ospedale San Raffaele）医学肿瘤科乳腺肿瘤中心负责人，同时担任 Vita-Salute San Raffaele 大学的副教授。

他于 2000 年毕业于米兰比可卡大学医学与外科学专业，并于 2004 年在米兰大学完成医学肿瘤学专科培训。

在培训期间，他曾作为访问科学家在多家美国顶尖机构开展研究，包括美国国家癌症研究所（NCI，贝塞斯达）、MD 安德森癌症中心（休斯敦）和耶鲁癌症中心（纽黑文）。

比安基尼教授拥有近 25 年的临床经验，主要负责早期及转移性乳腺癌患者的诊治，是国际公认的乳腺癌领域意见领袖。他特别关注新疗法的研究以及免疫治疗策略的开发。

他还负责医学肿瘤科的转化医学与免疫治疗研究团队，参与多项专注于乳腺癌患者的科研项目，致力于研究药物反应与耐药机制、探索新的治疗策略，并开发用于治疗个体化的生物标志物。

比安基尼教授发表了大量论文，刊登于 Nature, The Lancet, Annals of Oncology, The Lancet Oncology, Journal of Clinical Oncology, Nature Medicine, Nature Reviews Clinical Oncology 等国际顶级期刊。他经常受邀参加国内外专业会议与学术大会。

教育背景

米兰比可卡大学
医学学位 - 2000年

米兰比可卡大学
肿瘤内科专业学位 - 2004年

多媒体中心

出版物

Bianchini医生以作者身份在Journal Clinical Oncology、Lancet Oncology、Cancer Cell、journal National Cancer Institute、JAMA Oncology和Annals of Oncology等国际期刊上发表过大量文章。H指数为22。他经常参加意大利国内外的行业会议和专题研讨会。

最新出版物

Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers.
J Clin Oncol 28:4316-23, 2010
Bianchini G, Qi Y, Alvarez RH, Iwamoto T, Coutant C, Ibrahim NK, Valero V, Cristofanilli M, Green MC, Radvanyi L, Hatzis C, Hortobagyi GN, Andre F, Gianni L, Symmans WF, Pusztai L
Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer.
Cancer Res 70:8852-62, 2010
Bianchini G, Iwamoto T, Qi Y, Coutant C, Shiang C, Wang B, Santarpia L, Valero V, Hortobagyi GN, Symmans WK, Gianni L, Pusztai L.
扩展阅读
Biological processes associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer.
J Natl Cancer Inst 2010 Dec 29
Iwamoto T, Bianchini G, Booser D, QI Y, Coutant C, Shiang C, Santarpia L, Matsuoka J, Hortobagyi GN, Symmans WF, Holmes F, O'Shaughnessy J, Hellerstedt B, Pippen J, Andre F, Simon R, Pusztai
扩展阅读
Breast cancer genomics: challenges in interpretation and application.
Oncologist. 2013;18(4):e11-2
Kelly CM, Symmans WF, Andreopoulou E, Bianchini G
扩展阅读
Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers.
Breast Cancer Research 2013 15:R86
Bianchini G*, Pusztai L, Karn T, Iwamoto T, Rody A, Kelly CM, Muller V, Schmidt M, Qi Y, Holtrich U, Becker S, Santarpia L, Angelica F, Del Conte G, Zambetti M, Sotiriou C, Haibe-Kains B, Symmans WF, Gianni L
扩展阅读
An unmeet need: tailoring extended adjuvant endocrine therapy
British Journal of Cancer (2013), 1–4
Bianchini G, Gianni L
扩展阅读
The immune system and response to her2-targeted therapy in breast cancer.
The Lancet Oncology (2014) 15:e58-e68
Bianchini G, Gianni L
扩展阅读
Research-based pam50 subtype predictor identifies higher responses and improved survival outcomes in her2-positive breast cancer in the noah study.
Clin Cancer Res (2014) 20:511-21, 2014
Prat A, Bianchini G, Thomas M, Belousov A, Cheang MCU, Koehler A, Gómez P, Semiglazov V, Eiermann W, Tjulandin S, Byakhow M, Bermejo B, Zambetti M, Vazquez V, Gianni L, Baselga J
扩展阅读
Immune modulation of pathologic complete response after neoadjuvant her2-directed therapies in the neosphere trial.
Annals of Oncology 26(12): 2429-36
Bianchini G, Pusztai L, Pienkowski T, Im Y-H, Bianchi GV, Tseng L-M, Liu M-C, Lluch A, Galeota E, Magazzù D, Rodríguez J, Oh D-Y, Poirier B, Pedrini JL, Semiglazov V, Valagussa P, Gianni L
扩展阅读
Subtype specific metagene-based prediction of outcome after neoadjuvant and adjuvant treatment in breast cancer.
Clinical Cancer Research 22(2): 337-45
Callari M, Cappelletti V, D'Aiuto F, Musella V, Lembo A, Petel F, Karn T, Iwamoto T, Provero P, Daidone MG, Gianni L, Bianchini G*
扩展阅读
New strategies in breast cancer: immunotherapy.
Clin Cancer Res 22(9): 2105-10
Pusztai L, Karn T, Safonov A, Abu-Khalaf MM, Bianchini G
扩展阅读
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.
Nat Rev Clin Oncol Nov;13(11):674-690.
Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L
扩展阅读
Biomarker analysis of the neosphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of her2-positive breast cancer.
Breast Cancer Res 19(1): 16
Bianchini G, Kiermaier A, Bianchi GV, Im YH, Pienkowski T, Liu MC, Tseng LM, Dowsett M, Zabaglo L, Kirk S, Szado T, Eng-Wong J, Amler LC, Valagussa P, Gianni L
扩展阅读
Association between genomic metrics and immune infiltration in triple-negative breast cancer.
JAMA Oncology (doi:10.1001/jamaoncol.2017.2140)
Karn T, Jiang T, Hatzis C, Sänger N, El-Balat A, Rody A, Holtrich U, Becker S, Bianchini G, Pusztai L
扩展阅读
Is trastuzumab single agent obsolete in eraly breast cancer? No.
Breast. 2019 Feb;43:142-145
Bianchini G
扩展阅读